136 related articles for article (PubMed ID: 9758352)
1. Autologous reconstitution with BCR-ABL-negative haematopoiesis after T cell-depleted allogeneic BMT for CML.
Serrano J; Román J; Castillejo JA; Sánchez J; Navarro JA; Martín C; Herrera C; Torres A
Bone Marrow Transplant; 1998 Sep; 22(6):599-601. PubMed ID: 9758352
[TBL] [Abstract][Full Text] [Related]
2. Reconstitution with Philadelphia chromosome-negative recipient haematopoiesis early after allogeneic BMT for CML.
Sill H; Rule SA; Joske DJ; Chase A; Lin F; Goldman JM; Cross NC
Bone Marrow Transplant; 1996 Mar; 17(3):453-5. PubMed ID: 8704706
[TBL] [Abstract][Full Text] [Related]
3. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
Mackinnon S; Barnett L; Heller G
Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
[TBL] [Abstract][Full Text] [Related]
4. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
[TBL] [Abstract][Full Text] [Related]
5. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia.
Gardiner N; Lawler M; O'Riordan J; DeArce M; Humphries P; McCann SR
Bone Marrow Transplant; 1997 Aug; 20(3):235-41. PubMed ID: 9257892
[TBL] [Abstract][Full Text] [Related]
6. Detection of minimal residual disease and persistence of host-type hematopoiesis: a study in 28 patients after sex-mismatched, non-T cell-depleted allogeneic bone marrow transplantation for Philadelphia-chromosome positive chronic myelogenous leukemia.
Elmaagacli AH; Becks HW; Beelen DW; Stockova J; Bützler R; Opalka B; Schaefer UW
Bone Marrow Transplant; 1995 Dec; 16(6):823-9. PubMed ID: 8750276
[TBL] [Abstract][Full Text] [Related]
7. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
[TBL] [Abstract][Full Text] [Related]
9. Donor chimaerism is a strong indicator of disease free survival following bone marrow transplantation for chronic myeloid leukaemia.
Gardiner N; Lawler M; O'Riordan J; De'Arce M; McCann SR
Leukemia; 1997 Apr; 11 Suppl 3():512-5. PubMed ID: 9209441
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results.
Miyamura K; Barrett AJ; Kodera Y; Saito H
Bone Marrow Transplant; 1994 Aug; 14(2):201-9. PubMed ID: 7994233
[TBL] [Abstract][Full Text] [Related]
11. The evolving role of bone marrow transplantation in the treatment of chronic myelogenous leukemia.
Delage R; Ritz J; Anderson KC
Hematol Oncol Clin North Am; 1990 Apr; 4(2):369-88. PubMed ID: 2182597
[TBL] [Abstract][Full Text] [Related]
12. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
13. Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population.
Maury S; Belhadj K; Chami I; Kuentz M; Cordonnier C; Bories D
Bone Marrow Transplant; 2001 Oct; 28(7):717-20. PubMed ID: 11704798
[TBL] [Abstract][Full Text] [Related]
14. Durable molecular remission in a patient with chronic myelogenous leukemia and host-derived hematopoiesis after allogeneic bone marrow transplantation.
Wakui M; Okamoto S; Ishida A; Tanosaki R; Mori T; Kawai Y; Ohshima S; Ikeda Y
Bone Marrow Transplant; 1996 Oct; 18(4):801-4. PubMed ID: 8899199
[TBL] [Abstract][Full Text] [Related]
15. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Matsue K; Tabayashi T; Yamada K; Takeuchi M
Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
[TBL] [Abstract][Full Text] [Related]
16. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
17. Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse.
Serrano J; Román J; Herrera C; Castillejo JA; Navarro JA; Reina ML; González MG; Rodriguez MC; Pascual A; Sánchez J; Torres A
Bone Marrow Transplant; 1999 Mar; 23(5):475-82. PubMed ID: 10100562
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia.
Gardiner N; Lawler M; O'Riordan JM; Duggan C; De Arce M; McCann SR
Bone Marrow Transplant; 1998 Apr; 21(7):711-9. PubMed ID: 9578312
[TBL] [Abstract][Full Text] [Related]
19. [Clinical factors that affect the detection of BCR-ABL transcripts after allogenic bone marrow transplantation for chronic myeloid leukemia].
Román J; García MJ; Martín C; Sánchez J; Serrano J; Falcón M; Castillejo JA; Navarro JA; Flores R; Torres A
Med Clin (Barc); 1998 Oct; 111(11):405-9. PubMed ID: 9834912
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease in chronic myeloid leukaemia.
Cross NC
Hematol Cell Ther; 1998 Oct; 40(5):224-8. PubMed ID: 9844816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
